Background: Fatigue is a significant symptom in multiple sclerosis (MS) patients. First-generation disease modifying therapies (DMTs) are at best moderately effective to improve fatigue. Observations from small cohorts have indicated that natalizumab, an antibody targeting VLA-4, may reduce MS-related fatigue.
Objective: The TYNERGY study aimed to further evaluate the effects of natalizumab treatment on MS-related fatigue.
Methods: In this one-armed clinical trial including 195 MS patients, natalizumab was prescribed in a real-life setting, and a validated questionnaire, the Fatigue Scale for Motor and Cognitive functions (FSMC), was used both before and after 12 months of treatment to evaluate a possible change in the fatigue experienced by the patients.
Results: In the treated cohort all measured variables, that is, fatigue score, quality of life, sleepiness, depression, cognition, and disability progression were improved from baseline (all p values<0.0001). Walking speed as measured by the six-minute walk-test also increased at month 12 (p = 0.0016). All patients were aware of the nature of the treatment agent, and of the study outcomes.
Conclusion: Natalizumab, as used in a real-life setting, might improve MS-related fatigue based on the results from this one-armed un-controlled study. Also other parameters related to patients' quality of life seemed to improve with natalizumab treatment.
This is confirming what has been noticed before. Tysabri can improve fatigue and this study therefore indicates that if you can get rid of inflammation in the CNS then you can remove fatigue and other symptoms.
CoI: MouseDoctor - none. Prof G - multiple
Labels: depression and fatigue, Tysabri